Verrica Pharmaceuticals Inc.(VRCA)Earnings, Financials & Key RatiosVerrica Pharmaceuticals Inc. (VRCA) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's inability to achieve consistent profitability, combined with a $9.2 million quarterly cash burn and a $334.6 million accumulated deficit, suggests substantial ongoing liquidity and dilution risks.
Verrica Pharmaceuticals Inc. (VRCA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Verrica Pharmaceuticals Inc. (VRCA) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.41vs $0.59+30.5% | $5Mvs $5M+11.3% |
| Q2 2026 | Mar 11, 2026 | $0.56vs $0.43-30.2% | $5Mvs $5M+12.7% |
| Q4 2025 | Nov 14, 2025 | $0.13vs $1.14+111.4% | $14Mvs $5M+217.3% |
| Q3 2025 | Aug 12, 2025 | $0.02vs $0.70+102.9% | $13Mvs $6M+96.9% |
Recent stock market news and headlines for Verrica Pharmaceuticals Inc. (VRCA)
– Development Partner Torii Pharmaceutical also recently announced dosing of the first Japanese patient in this trial evaluating YCANTH (TO-208) in Japan –
- Development Partner Torii Pharmaceutical also recently announced dosing of the first Japanese patient in this trial evaluating YCANTH (TO-208) in Japan - - Verrica maintains ownership of global rights to YCANTH for all indications in all territories outside of Japan, including common warts - WEST CHESTER, Pa.
Key metrics vs top competitors for Verrica Pharmaceuticals Inc. (VRCA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.94 | $63.27M | -3.54 | 370.22% | -50.27% | -240.35% | — | |
| $7.04 | $193.75M | -14.98 | 10.2% | -14.82% | -35.57% | — | |
| $10.31 | $1.43B | -1.00 | -2.75% | -43.5% | -50.65% | — | |
| $15.78 | $1.8B | -12.93 | 8.28% | -25.66% | -50.82% | — | |
| $0.72 | $93.03M | -4.49 | -10.02% | -2.03% | -9.41% | — | |
| $3.06 | $1.06B | 35.87 | 0.57% | 3.74% | 4.75% | — |
Verrica Pharmaceuticals Inc. (VRCA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verrica Pharmaceuticals Inc. (VRCA) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 12, 2026·SEC
Mar 11, 2026·SEC
Dec 30, 2025·SEC
Get notified when VRCA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Verrica Pharmaceuticals Inc. (VRCA) stock FAQ — growth, dividends, profitability & financials explained
Verrica Pharmaceuticals Inc. (VRCA) reported $37.2M in revenue for fiscal year 2025.
Verrica Pharmaceuticals Inc. (VRCA) grew revenue by 370.2% over the past year. This is strong growth.
Verrica Pharmaceuticals Inc. (VRCA) reported a net loss of $17.8M for fiscal year 2025.
Verrica Pharmaceuticals Inc. (VRCA) has a return on equity (ROE) of -240.4%. Negative ROE indicates the company is unprofitable.
Verrica Pharmaceuticals Inc. (VRCA) had negative free cash flow of $14.1M in fiscal year 2025, likely due to heavy capital investments.
